Momenta Pharmaceuticals Names Vice President, Strategic Product Development
CAMBRIDGE, Mass., May 23 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced the appointment of Barbara Rosengren as Vice President, Strategic Product Development.
Ms. Rosengren will be responsible for overseeing project and portfolio management for the Company, and providing strategic leadership for several of our key projects and external alliances and collaborations. She will report to Steven B. Brugger, Senior Vice President, Strategic Business Operations.
"Barbara brings a wealth of pharmaceutical and biotech industry experience to Momenta," said Mr. Brugger. "She has led global project teams from IND submission through FDA approval and product launch, and managed multiple external collaborations with global pharmaceutical partners. As we broaden our development pipeline and move closer to commercialization, we expect that Barbara's participation on Momenta's senior leadership team will contribute to our regulatory and commercial success on these opportunities."
Ms. Rosengren's most recent experience includes Millennium Pharmaceuticals, where she was Vice President and Product Development Leader, and led project teams for several early and late phase development programs and managed related collaborations with industry partners. Prior to Millennium, she spent 19 years at Novartis Pharmaceuticals holding various senior leadership positions, including Vice President, U.S. New Product Commercialization, and Vice President, Global Corporate Project Management.
Ms. Rosengren received her B.A. in Education and Sociology, summa cum laude, from Tufts University, an M.A. in Economics from the University of Michigan, and her M.B.A. from the Wharton School of the University of Pennsylvania.
Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic versions of sugar-based and biologic drug products. The Company's most advanced product candidate is M-Enoxaparin, a technology-enabled generic version of Lovenox®. Based on its understanding of complex sugars, Momenta has created a diversified pipeline of near-term product opportunities, novel development products and discovery candidates. Momenta was founded in 2001 and is headquartered in Cambridge, MA.
To receive additional information about Momenta, please visit our website at http://www.momentapharma.com, which does not form a part of this press release.
Forward Looking Statements:
Statements in this press release regarding Momenta Pharmaceuticals Inc.'s future expectations, beliefs, goals, plans or prospects constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Momenta's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including those factors contained in Momenta's Annual Report on Form 10-K for the year ended December 31, 2004 filed with the Securities and Exchange Commission under the section "Risk Factors That May Affect Results," as well as other documents that may be filed by Momenta from time to time with the Securities and Exchange Commission. Forward-looking statements include statements regarding Momenta's expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "anticipate", "believe", "could", "estimate", "expect", "intend", "may", "should", "will", and "would" or similar words. Momenta assumes no obligations to update the information included in this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
SOURCE Momenta Pharmaceuticals, Inc. -0- 05/23/2005 /CONTACT: Michael A. Lawless of Momenta Pharmaceuticals, Inc., +1-617-395-5189 / /Web site: http://www.momentapharma.com/ (MNTA)